Form 4: Sarepta Therapeutics Executive Louise Rodino-Klapac Reports Stock Transaction
SEC Form 4 Filing
Sarepta Therapeutics' Head of R&D, Louise Rodino-Klapac, sold 4,558 shares to cover tax obligations and now holds 67,630 shares.
Summary
- Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reported a transaction involving the company's stock.
- On November 18, 2024, 4,558 shares of common stock were disposed of to cover tax obligations related to vesting of restricted stock units.
- The shares were sold at a price of $102.89 per share.
- Following the transaction, Rodino-Klapac beneficially owns 67,630 shares of Sarepta Therapeutics stock.
- This total includes 47 shares purchased through the company's Employee Stock Purchase Plan on August 30, 2024.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a stock transaction by an executive. It does not indicate any positive or negative sentiment about the company's performance or future prospects.
Industry Context
This is a routine filing related to insider transactions and is common for executives who receive stock-based compensation. It provides transparency into the trading activities of company insiders.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
- The transaction is typical for executives who receive stock options or restricted stock units as part of their compensation, often selling shares to cover tax liabilities upon vesting.
- Similar filings are made by executives at comparable biotech companies such as BioMarin, Vertex Pharmaceuticals, and Regeneron, whenever they trade company stock.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it is a routine sale of shares by an executive.
- The sale does not indicate any change in the company's fundamentals or future outlook.
Key Dates
| Date | Description |
|---|---|
| 08/30/2024 | 47 shares purchased under the Company's registered Employee Stock Purchase Plan. |
| 11/18/2024 | Date of the stock transaction where 4,558 shares were disposed of. |
| 11/20/2024 | Date the Form 4 was signed. |
Keywords
Sarepta Therapeutics, stock transaction, insider trading, Form 4, Louise Rodino-Klapac, executive stock, tax obligations, employee stock purchase plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.